Oncology drug developer Celsion is touting a study that supports the effectiveness of its ThermoDox pharmaceutical in combination with radiofrequency ablation (RFA) in patients with primary liver cancer.
The study showed that using RFA in combination with ThermoDox resulted in increased burn time per tumor volume, which substantially improved overall survival in patients with liver cancer, compared with patients treated with RFA alone.
The results come from a U.S. National Institutes of Health (NIH) analysis of the HEAT study, a 701-patient study investigating ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin used in combination with RFA for patients with primary liver cancer.
The findings are consistent with Celsion's analysis of HEAT study data showing that in patients treated with RFA for more than 45 minutes, standardized RFA plus ThermoDox resulted in a statistically significant improvement in overall survival versus standardized RFA alone.
The study will be presented at RSNA 2016.
